TP53 and acute myeloid leukemia: When analyzed within the AML-MRC-C group, the TP53 mutation predicted a shorter OS not only in all patients (p = 0.006), but also in those receiving any treatment (p = 0.010) in the univariate analysis for OS (Table 2).